BHR - GPSIs (GPs with Special Interest) in Rheumatology
16 Jul 2020
As the focus shifts to re-establishing of services following response to the Covid-19 pandemic, we need to manage the backlog of patients as well managing incoming demand. Following discussion with the Trust clinicians, we would like to adopt a model of care where GPSIs can work in the community in collaboration with consultants from secondary care.
In response to the Covid-19 pandemic, all Local Improvement Schemes (LIS) were stopped to allow primary care capacity to be redeployed. As the pandemic is now more stable, the LIS schemes will restart on the 1 July.
Having IBD does not put you in a high risk group, so if you are on no medications for it, are on topical therapy only, or oral mesalasine (Salofalk, asacol, pentasa, octasa) then you are not considered to be in a vulnerable group and should follow guidance for the general public.